智通财经APP获悉，美银证券发布研报称，将华润医药(03320)目标价由5.9港元下调至5.7港元，重申"买入"评级。该行表示华润医药上半年业绩稳定，收入年度同比增长2%，毛利年度同比微升0.1%，毛利率则年度同比下降0.3个百分点至16%，纯利年度同比增长5.3%。该行基于华润医药上半年的业绩，调整了各个业务的收入预测，下调公司2026至2028年的收入预期4%、4%及5%，同时因业务扩张上调2026年起行政开支比率预测0.1个百分点。整体而言，该行下调2026至2028年各年盈利预测各6%、7%及7%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.